| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.4M | — | -6.2% |
| Cost of Revenue | $334K | — | +36.3% |
| R&D Expense | $3.2M | — | +67.7% |
| SG&A Expense | $1.7M | — | +1.5% |
| Operating Income | -$3.6M | — | -97.1% |
| Pre-tax Income | -$3.5M | — | -116.8% |
| Income Tax | $8K | — | +14.3% |
| Net Income | -$3.5M | — | -116.4% |
| EPS (Basic) | -$0.16 | — | -100.0% |
| EPS (Diluted) | -$0.16 | — | -100.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.6M | -37.0% | -45.9% |
| Accounts Receivable | $2.4M | -20.5% | -15.4% |
| Current Assets | $24.5M | -13.3% | -19.5% |
| Total Assets | $33.2M | -10.7% | -16.8% |
| Current Liabilities | $6.9M | -8.4% | +4.8% |
| Stockholders' Equity | $22.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.7M | — | +8.9% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | -$16K | — | +99.0% |
| Financing Cash Flow | $0 | — | +100.0% |
| Free Cash Flow | -$2.7M | — | +10.3% |
| -22.3% |